<DOC>
	<DOCNO>NCT00558025</DOCNO>
	<brief_summary>The objective trial conduct early Parkinson 's disease ( PD ) patient : - To assess patient early Parkinson 's disease ( PD ) successfully switch ( overnight switch ) Pramipexole ( PPX ) Immediate Release ( IR ) Pramipexole Extended Release ( ER ) . A successful switch specific visit define worsen Unified Parkinsons Disease Rating Scale ( UPDRS ) part II+III score 15 % baseline drug-related adverse event lead withdrawal ; - To establish successful switch obtain without dose-adaptation ; - To provide information conversion ratio ( mg : mg ) Pramipexole IR Pramipexole ER .</brief_summary>
	<brief_title>Overnight Switch Trial From Pramipexole IR Pramipexole ER Patients With Early Parkinson Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Male female patient idiopathic Parkinson 's disease ( PD ) confirm least two follow sign : rest tremor , bradykinesia , rigidity . 2 . Parkinson 's disease diagnose within 5 year . 3 . Patients 30 year age old time diagnosis . 4 . Modified Hoehn Yahr stage 1 3 . 5 . Patients receive pramipexole IR least three month prior baseline visit ( randomization visit , V2 ) . 6 . Pramipexole dose optimize ( accord investigator¿s judgement ) , great equal 1.5 mg/day , stable equally divide 3 time per day , least 4 week prior baseline visit ( V2 ) . 7 . Patients willing able comply schedule visit , treatment plan , laboratory test study procedure . 8 . Signed informed consent obtain study procedure carry accordance International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline local legislation ) . 1 . Motor complication levodopa therapy V1 . 2 . Atypical parkinsonian syndrome due drug , metabolic disorder , encephalitis degenerative disease . 3 . Dementia , define MiniMental State Exam score &lt; 24 V1 4 . Any psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criteria 5 . History psychosis , except history drug induce hallucination 6 . Clinically significant electrocardiogram ( ECG ) abnormalities V1 . 7 . Clinically significant hypotension either screen visit baseline visit . 8 . Malignant melanoma history previously treat malignant melanoma . 9 . Any clinically significant disease 10 . Pregnancy breastfeed . 11 . Sexually active female childbearing potential 12 . Serum level Aspartate Aminotransferase ( Serum Glutamic Oxaloacetic Transaminase ) ( AST ( SGOT ) ) , Alanine Aminotransferase ( Serum Glutamate Pyruvate Transaminase ) ( ALT ( SGPT ) ) , alkaline phosphatase bilirubin &gt; 2 Upper Limit Normal ( ULN ) ( screen lab test ) . 13 . Patients creatinine clearance &lt; 50 mL/min 14 . Any dopamine agonist ( except pramipexole IR ) within three month prior baseline visit . 15 . History discontinuation treatment pramipexole IR 16 . Previous treatment pramipexole ER . 17 . Any medication ( include intramuscular formulation ) central dopaminergic antagonist activity within 4 week prior baseline visit ( i.e . typical neuroleptic , atypical antipsychotic , reserpine , methyldopa , centrallyactive antiemetic , etc ) . 18 . Any following drug within 4 week prior baseline visit : methylphenidate , cinnarizine , amphetamine . 19 . Flunarizine within 3 month prior baseline visit . 20 . Known hypersensitivity Pramipexole excipients . 21 . Drug abuse ( include alcohol ) , accord Investigator¿s judgement , within 2 year prior screen . 22 . Participation investigational drug study use investigational drug within 4 week five time halflife investigational drug ( whichever longer ) prior baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>